Companies are said to be fundamentally strong based on excellent financials, such as significant profit growth, a low debt-to-equity ratio, and continuous cash flow. Companies with strong financials will continue to expand and operate regardless of market conditions.
Listed below are three small-cap stocks under Rs 150
Manappuram Finance Ltd
Manappuram Finance is a Non-Banking Finance Company, which provides a wide range of fund-based and fee-based services.
Manappuram Finance has been categorized as a small-cap stock with a market capitalization of Rs 12,467 crore. On Friday, shares were trading at Rs 148.30 per share, up 1.26 percent over the previous close.
The stock has climbed 31 percent in the last six months and 37 percent in the last year.
Manappuram Finance reported a return on equity ratio of 15.51 percent, and the return on capital employed is 25.53 percent, while margins are increasing, with a net profit margin of 22.44 percent.
The company’s revenue grew by 10 percent yearly, from Rs 6,061 crore in FY 21-22 to Rs 6,684 crore in FY 22-23, For the same timeframe, Net profit increased by 13 percent from Rs 1,328 crore to Rs 1,500 crore.
As per the latest shareholding pattern, foreign institutional investors hold 30.73 percent stake in the company and Domestic institutional investors hold 10.69 percent.
Man Infraconstruction Ltd
Man Infraconstruction Limited is an integrated EPC (Engineering, Procurement & Construction) company that is engaged in the Residential, Commercial & Industrial and Road construction segments.
Man Infraconstruction is a small-cap stock with a market capitalization of Rs 5,191 crore. On Friday, shares were trading at Rs 139.95 a share, down 2.71 percent from the previous close.
The stock has climbed by 72 percent in the last six months and by 57 percent in the last year.
Man Infra construction has adequate return ratios, with a return on equity of 23.73 percent and a return on capital employed of 38.41 percent, while margins are improved, with a net profit margin of 15.03 percent and an operating margin of 23.83 percent.
Revenue climbed by 96 percent year on year, rising from Rs 961 crore in FY 21-22 to Rs 1,890 crore in FY 22-23. Net profit fell from Rs 297 crore to Rs 284 crore within the same period.
According to the most recent shareholding pattern, foreign institutional investors own 2.3 percent of the firm, while promoters own 67.12 percent.
Marksans Pharma Ltd
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
With a market value of Rs 5,376 crore, Marksans Pharma is classified as a small-cap stock. Shares were trading at Rs 117.50 a share on Friday, down 1.01 percent from the previous close.
In the previous six months, the stock has increased 79 percent, and in the last year, it has gained 138 percent.
Marksans Pharma’s return on equity stands at 15.25 percent and a return on capital employed at 18.75 percent, while margins are rising, with a net profit margin of 14.32 percent.
The company’s revenue grew by 24 percent yearly, from Rs 1,490 crore in FY 21-22 to Rs 1,852 crore in FY 22-23, For the same timeframe, Net profit increased by 42 percent from Rs 186 crore to Rs 265 crore.
As per the latest shareholding pattern, foreign institutional investors hold 14.9 percent stake in the company and Domestic institutional investors hold 3.65 percent.
Written by Omkar Chitnis
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
